Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07432659 · ClinicalTrials.gov registry record · NA

Add-On ZIDA Sock Therapy for Overactive Bladder

A NA study of Overactive Bladder, sponsored by Medical University of South Carolina.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT07432659 is a NA study of Overactive Bladder that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 20 participants, below the 211-participant average among 45 other Overactive Bladder trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07432659, a NA study of Overactive Bladder, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

Many people with overactive bladder (OAB) continue to experience symptoms despite pharmacologic treatment. This study evaluates the use of the ZIDA Control Sock, an FDA-cleared, noninvasive wearable device that delivers mild electrical stimulation near the ankle, as an adjunct to usual care. Adults with OAB-wet who remain symptomatic on stable medication will use the device at home once weekly for 12 weeks while continuing their prescribed therapy. The study collects clinical, patient-reported, and safety information during adjunctive device use.

Conditions Studied

Interventions

  • DEVICE ZIDA Control Sock

Study Locations (1)

South Carolina

  • Rutledge Tower at Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-03
Est. Completion 2028-03
Phase NA

What the Registry Record Tells You About NCT07432659

The ClinicalTrials.gov registry entry for NCT07432659 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 211-participant average among 45 other Overactive Bladder trials with a reported enrollment target (91% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Overactive Bladder appearing as the primary indexed condition, and to 1 intervention - of which ZIDA Control Sock is the first listed.

NCT07432659 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.

Frequently Asked Questions

What is clinical trial NCT07432659 about?

NCT07432659 is a clinical study titled "Add-On ZIDA Sock Therapy for Overactive Bladder". Many people with overactive bladder (OAB) continue to experience symptoms despite pharmacologic treatment. This study evaluates the use of the ZIDA Control Sock, an FDA-cleared, noninvasive wearable device that delivers mild electrical stimulation near the ankle, as an adjunct to usual care. Adults ...

What is the current status of trial NCT07432659?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2026-03. Estimated completion is 2028-03.

What conditions does trial NCT07432659 study?

This clinical trial studies the following conditions: Overactive Bladder.

What interventions are being tested in trial NCT07432659?

The interventions under investigation include: ZIDA Control Sock (DEVICE).

Who is sponsoring clinical trial NCT07432659?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07432659 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overactive Bladder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.